TRMU (tRNA Mitochondrial Uridine Synthetase), also known as MTU1 (Mitochondrial tRNA-specific pseudouridine synthase 1), encodes a crucial mitochondrial tRNA-modifying enzyme that catalyzes the 2-thiolation of uridine at wobble positions of mitochondrial tRNAs. This modification is essential for proper mitochondrial translation and function. TRMU deficiency is associated with a spectrum of mitochondrial disorders including acute infantile liver failure, sensorineural hearing loss, and cardiomyopathy.
| Attribute |
Value |
| Gene Symbol |
TRMU |
| Full Name |
tRNA Mitochondrial Uridine Synthetase (MTU1) |
| Aliases |
MTU1, tRNA Mitochondrial Uridine Synthase, Mtu1 |
| Chromosomal Location |
22q13.33 |
| NCBI Gene ID |
55687 |
| OMIM ID |
610230 |
| Ensembl ID |
ENSG00000100412 |
| UniProt ID |
Q9BRR4 |
TRMU encodes a mitochondrial matrix enzyme that catalyzes the 2-thiolation of uridine residues at the wobble position of mitochondrial tRNAs, specifically tRNALys, tRNAGlu, and tRNAGln [1][2]. This modification forms 5-taurinomethyl-2-thiouridine (tm5s2U) moieties, which are critical for:
- Mitochondrial translation fidelity: The thiolated uridine at the wobble position enhances codon-anticodon pairing accuracy, particularly for A-ended codons
- Respiratory chain function: Proper mitochondrial translation is essential for assembling the OXPHOS complexes
- Cellular energy production: Functional OXPHOS complexes I, III, and IV require properly translated mitochondrial-encoded subunits
- Iron-sulfur cluster biogenesis: Mitochondrial translation defects can impair ISC assembly machinery
The enzyme works in coordination with other mitochondrial tRNA modification proteins including GTPBP3 and MTO1, forming a modification complex that ensures proper tRNA maturation [3].
TRMU contains several functional domains:
- N-terminal mitochondrial targeting sequence
- Central catalytic domain with conserved cysteine residues essential for thiolation activity
- C-terminal domain involved in tRNA recognition and binding
¶ Pathogenic Variants and Disease Associations
Homozygous or compound heterozygous pathogenic variants in TRMU cause acute infantile liver failure due to synthesis defect of mtDNA-encoded proteins. The disease presents in infancy with:
- Severe liver dysfunction
- Elevated transaminases
- Hypoglycemia
- Variable neurological involvement
A study described three new cases with TRMU mutations, expanding the phenotypic spectrum [4]. The disease can be responsive to cysteine supplementation in some patients [5][6].
TRMU acts as a nuclear modifier influencing the severity of deafness caused by mitochondrial 12S rRNA mutations (e.g., m.1555A>G and m.1494C>T) [7][8]. Individuals with these mitochondrial mutations who also carry TRMU variants often exhibit more severe hearing loss phenotypes. This modification is particularly important because:
- The 12S rRNA mutation predisposes to aminoglycoside-induced hearing loss
- TRMU variants can accelerate the onset and severity of hearing impairment
- Genetic correction of TRMU alleles has shown promise in restoring mitochondrial function in patient-derived cells [9]
¶ Cardiomyopathy and Exercise Intolerance
Some TRMU variant carriers develop cardiomyopathy and exercise intolerance due to impaired mitochondrial respiratory chain function. The heart, with its high energy demands, is particularly vulnerable to mitochondrial translation defects.
Studies have shown that TRMU expression is downregulated in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) syndrome, contributing to mt-tRNA hypomodification and mitochondrial dysfunction [10]. This suggests potential therapeutic relevance for TRMU-targeted interventions in MELAS.
Pathogenic TRMU variants lead to:
- Reduced thiolation activity: Loss of 2-thiouridine modification impairs codon recognition
- Mitochondrial translation deficiency: Aberrant tRNA function causes misreading and decreased translation efficiency
- Respiratory chain dysfunction: Reduced synthesis of mtDNA-encoded OXPHOS subunits
- Proteolytic degradation: Mutant TRMU can promote proteolysis of the protein itself via mitochondrial caseinolytic peptidase (CLPP) [11]
- Cellular stress response: Mitochondrial dysfunction triggers integrated stress response pathways
Cysteine supplementation has emerged as a potential treatment for some TRMU deficiency cases. The rationale is that cysteine provides sulfur for the thiolation reaction, potentially bypassing partial enzyme deficiency [5][6]. However, response varies based on specific variant and tissue involvement.
TRMU and mitochondrial tRNA modification have emerged as relevant to neurodegenerative diseases:
Recent research has identified altered TRMU expression in AD brains:
- Reduced TRMU levels in hippocampal and cortical regions
- Contributes to mitochondrial translation deficits observed in AD
- May exacerbate energy failure and synaptic dysfunction
Mitochondrial tRNA modifications are altered in PD:
- TRMU-mediated 2-thiolation is reduced in PD patient tissues
- Contributes to mitochondrial dysfunction in dopaminergic neurons
- May sensitize neurons to environmental toxins
The connection between TRMU and neurodegeneration involves several mechanisms:
- Energy failure: Mitochondrial translation defects reduce OXPHOS capacity
- Oxidative stress: Impaired electron transport chain increases ROS production
- Calcium dysregulation: Mitochondrial dysfunction affects calcium homeostasis
- Aging susceptibility: Age-related decline in tRNA modification exacerbates vulnerability
Zebrafish deletion of Mtu1 (the TRMU ortholog) revealed the essential role of tRNA modification in mitochondrial biogenesis and hearing function [12]. The model demonstrated:
- Severe mitochondrial dysfunction
- Developmental abnormalities
- Auditory deficits
- Phenocopying human disease features
TRMU variants should be considered in:
- Infants with unexplained liver failure
- Patients with sensorineural hearing loss, especially with mitochondrial 12S rRNA mutations
- Families with autosomal recessive mitochondrial disorders
- Patients with cardiomyopathy and exercise intolerance
- Individuals with early-onset neurodegeneration
- Cysteine supplementation trials for TRMU deficiency
- Avoidance of aminoglycosides in individuals with TRMU variants and mitochondrial 12S rRNA mutations
- Monitoring for cardiomyopathy in TRMU variant carriers
- Co-factors targeting mitochondrial function (riboflavin, L-carnitine, CoQ10)
TRMU represents a potential therapeutic target:
- Small molecule activators: Compounds enhancing TRMU activity
- Gene therapy: Viral delivery of wild-type TRMU
- tRNA modifications: Stabilizing mitochondrial tRNA structure
- Combination approaches: Targeting multiple steps in mitochondrial translation
¶ Research Models and Future Directions
- Zebrafish Mtu1 knockout: Phenocopies human disease
- Mouse models: Conditional knockouts for tissue-specific studies
- Drosophila models: Genetic modifier screening
- Understanding the precise mechanisms of TRMU-mediated neurodegeneration
- Developing TRMU-targeted therapeutic compounds
- Identifying biomarkers for patient selection
- Exploring combination therapies for mitochondrial diseases
- Investigating age-related decline in tRNA modification
TRMU (also known as Mtu1) contains several critical structural features:
N-terminal mitochondrial targeting sequence:
- ~30 amino acid presequence
- Amphipathic helix structure
- Cleaved upon mitochondrial import
Central catalytic domain:
- Contains conserved cysteine residues (Cys-456, Cys-458, Cys-460)
- Forms the active site for 2-thiolation
- Requires iron-sulfur cluster for activity
C-terminal domain:
- tRNA recognition motifs
- Dimerization interface
- Regulatory elements
The 2-thiolation of mitochondrial tRNAs involves:
- Sulfur transfer: Cysteine residues serve as sulfur donors
- Iron-sulfur cluster: [2Fe-2S] cluster required for activity
- tRNA binding: Recognition of wobble uridine
- Thiolation: Formation of 2-thiouridine derivatives
- Product release: Modified tRNA for translation
TRMU functions within a larger modification network:
| Protein |
Function |
Interaction |
| GTPBP3 |
mt-tRNA modification |
Cooperative modification |
| MTO1 |
Modification enzyme |
Complex formation |
| MTU1 (TRMU) |
2-thiolation |
Central enzyme |
| MSS1 |
Sulfur donor |
Provides sulfur |
| ABCB7 |
Iron-sulfur cluster |
Cluster transfer |
The cooperative modification pathway:
- GTPBP3/MTO1 catalyze initial modifications
- TRMU performs 2-thiolation
- Cooperative effects enhance efficiency
- Modified tRNAs support accurate mitochondrial translation
¶ Prevalence and Epidemiology
TRMU-related disorders are rare:
- Estimated prevalence: 1:100,000 - 1:500,000
- More common in populations with founder mutations
- Both males and females affected
- No ethnic predominance identified
Diagnosing TRMU-related disease presents challenges:
- Phenotypic variability
- Overlap with other mitochondrial disorders
- Specialized testing required
- Limited availability of genetic testing
Current management strategies:
- Supportive care for organ dysfunction
- Cysteine supplementation in responsive cases
- Avoidance of aminoglycosides
- Cardiac monitoring
- Hearing evaluation and support
- Enzyme activators: Small molecules enhancing TRMU function
- Gene therapy: AAV-mediated TRMU delivery
- tRNA therapeutics: Modified tRNA administration
- Mitochondrial supplements: CoQ10, L-carnitine, riboflavin
Diagnostic and monitoring biomarkers:
- Genetic testing: Sequencing of TRMU coding regions
- Biochemical markers: Mitochondrial translation assays
- Expression analysis: TRMU levels in patient cells
- Functional assays: tRNA modification analysis
¶ TRMU and Aging
TRMU function may decline with age:
- Reduced tRNA modification efficiency
- Accumulation of translational errors
- Progressive mitochondrial dysfunction
- Connection to age-related neurodegeneration
Age-related TRMU decline may contribute to:
- Increased oxidative stress
- Mitochondrial DNA mutation accumulation
- Cellular energy deficits
- Susceptibility to neurodegenerative disease
¶ Animal Models and Research Insights
The zebrafish (Danio rerio) has proven an invaluable model for studying TRMU function:
Mtu1 Knockout Phenotype:
- Developmental arrest at early stages
- Mitochondrial dysfunction in multiple tissues
- Cardiac abnormalities
- Neurological defects
- Phenocopying human mitochondrial disease
Morpholino Studies:
- Partial knockdown reveals dose-dependent effects
- Tissue-specific vulnerability
- Rescue experiments with human TRMU mRNA
Murine models have provided additional insights:
- Conditional knockouts: Tissue-specific deletion
- Knock-in models: Patient-specific mutations
- Transgenic overexpression: Rescue studies
Fibroblast Studies:
- Patient-derived fibroblasts show reduced thiolation
- Respiratory chain deficiency
- Sensitivity to oxidative stress
iPSC-Derived Neurons:
- Neuronal differentiation defects
- Mitochondrial dysfunction
- Disease modeling potential
| Approach |
Mechanism |
Stage |
Notes |
| Cysteine supplementation |
Provide sulfur source |
Clinical |
Variable response |
| CoQ10 |
Support ETC |
Preclinical |
May help energy |
| L-carnitine |
Metabolic support |
Research |
Mitochondrial health |
| NAD+ precursors |
Enhance mitochondrial function |
Preclinical |
PGC-1alpha activation |
- AAV vectors: CNS delivery
- CRISPR correction: Variant-specific
- mRNA delivery: Transient expression
- MitoQ: Mitochondrial-targeted antioxidant
- Idebenone: ETC support
- Vitamin C: Antioxidant support
- Genetic testing: Targeted panels or WES
- Biochemical testing: Complex activity in muscle
- Functional assays: Patient cell analysis
Acute Management:
- Supportive care for liver failure
- Management of seizures
- Cardiac monitoring
Long-term Management:
- Cysteine supplementation trials
- Avoidance of aminoglycosides
- Regular cardiac evaluation
- Physical therapy
- Infantile onset: Variable, can be severe
- Later onset: Generally better prognosis
- Modifier genes: Influence disease severity
TRMU orthologs are found across eukaryotes:
| Species |
Gene |
Identity |
| Human |
TRMU |
100% |
| Mouse |
TruMU |
94% |
| Zebrafish |
mtu1 |
78% |
| Yeast |
MSK1 |
55% |
The thiolation function is evolutionarily conserved from bacteria to mammals, indicating its fundamental importance in mitochondrial translation.
- tRNA sequencing: Modified nucleoside analysis
- Northern blotting: tRNA modification status
- Mitochondrial translation assays: Protein synthesis measurement
- Respirometry: OCR measurements
- Proteomics: OXPHOS complex analysis
- Yeast genetics: Functional complementation
- Cell-free systems: In vitro translation
- Cryo-EM: Structure determination
Mitochondrial diseases collectively affect approximately 1 in 5,000 individuals, with TRMU-related disease representing a small but significant subset.
- Healthcare costs for mitochondrial disease
- Loss of productivity
- Caregiver burden
- Improved diagnostic capacity
- Newborn screening considerations
- Family planning support
- Structure-function studies: Mechanism of thiolation
- Biomarker development: Disease progression markers
- Therapeutic screening: Drug discovery
- Gene therapy optimization: Safe delivery
- Effective treatments for severe disease
- Biomarkers for treatment response
- Understanding of tissue specificity
- Prevention strategies